The American College of Cardiology’s 73rd Annual Scientific Session & Expo (ACC24) took place over the weekend in Atlanta, spotlighting the latest and most impactful innovations in the field of cardiovascular care.
Tag Archive for: Jardiance
Boehringer Ingelheim is concentrating on expanding its pipeline beyond Jardiance and other key products.
All 10 pharmaceutical companies whose products were selected for the first round of Medicare drug price negotiations have agreed to participate in the talks, the Department of Health and Human Services announced Tuesday.
The Biden administration on Tuesday released its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people, with big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer among them.
The U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim’s drugs Jardiance and Synjardy to treat type 2 diabetes in children.
Boehringer Ingelheim and Eli Lilly said their diabetes drug Jardiance was shown to slow the progression of chronic kidney disease (CKD), as they seek to catch up with market segment leader AstraZeneca.
For all its forays elsewhere, diabetes remains the bedrock of Lilly’s business – and, if the Mounjaro launch goes as hoped, will continue to be so for a long time to come.
AstraZeneca’s blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalization and death in people with all types of heart failure, according to study data released on Saturday, opening the door to a substantial increase in patients who could benefit.
